PFE

From a fundamental perspective, Pfizer's financials show a mixed picture. The company has a market capitalization of $143.68 billion and a price-to-earnings (P/E) ratio of 19.2, which is relatively attractive compared to its forward P/E of 8.6. However, the earnings per share (EPS) of $1.31 has seen a quarter-over-quarter decline of 10.1%, raising concerns about profitability. Revenue growth has been positive at 5.4% quarter-over-quarter, but the year-over-year growth is troubling at -164.7%, indicating a significant contraction in revenue. The gross margin stands at an impressive 7033.3%, while the operating margin is also strong at 2466.8%. Analysts have a consensus rating of HOLD, with two strong buys, nine buys, and fifteen holds, reflecting cautious optimism with a target price of $29.19.

Looking ahead, Pfizer does not have any scheduled earnings within the next 30 days, which may limit immediate catalysts for price movement. The last earnings report was for the quarter ending March 31, 2026, and investors are particularly focused on the implications of the CFO transition and whether it will lead to improved operational performance. The key metric to monitor will be the trajectory of revenue growth, especially in light of the recent significant decline, and how effectively the company can leverage its investments in new drug pipelines, particularly regarding its obesity treatments, which analysts believe could be pivotal for the stock's recovery by 2028.